Health Catalyst, Inc. (HCAT) is a publicly traded company in the Healthcare — Medical - Healthcare Information Services industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Health Catalyst, Inc. equips healthcare providers with crucial data and analytical technologies, alongside specialized services. Their extensive product line features a robust, enterprise-level data and analytics platform designed specifically for the healthcare sector. They additionally offer advanced artificial intelligence (AI) and data science solutions that integrate AI seamlessly into existing business intelligence tools, thereby enhancing analytical precision.
Analysis Summary
Health Catalyst, Inc. reported revenue of $311.1M in the most recent fiscal year, growing at a 5-year CAGR of 10.5%.
Trailing-twelve-month margins: gross margin 46.4%, operating margin -19.7%, net margin -90.6%.
At the current price of $1.73, HCAT has negative trailing earnings (P/E not meaningful) and an ROE of -129.70%. Market capitalisation stands at $128M.
Balance sheet quality for HCAT: current ratio of 1.9, net debt of $75.5M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Price
| Price | $1.73 |
| Market Cap | $128M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 1.28 |
| EV / EBITDA | -1.25 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -129.70% |
| Return on Invested Capital | -21.13% |
| Return on Assets | -73.85% |
| Gross Margin | 46.44% |
| Operating Margin | -19.67% |
| Net Margin | -90.61% |
Financial Health
| Debt / Equity | 1.69 |
| Current Ratio | 2.70 |
What to look at in Healthcare / Pharma
The R&D pipeline is the invisible asset. Patents expiring = revenues evaporating. Look at innovation and cash flow.
- R&D / Revenue — Shows investment in future pipeline. Serious pharma reinvests 15-20%
- 5y EPS growth — After patent expirations, are they still growing?
- Gross margin — Branded pharma >70%. Generics much lower — defines the business type
- FCF / Net Income — Earnings quality — big pharma should convert >90%
- ROIC — Capital reinvested efficiently — key in pharma due to long R&D cycles
- Net debt / EBITDA — Pharma acquisitions pile up debt — watch the post-M&A picture
- P/E vs own 10y history — The best comparison is with its own history, not with peers
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| HCAT | Health Catalyst, Inc. | $128M | 1.28 | -129.7% | |
| TEM | Tempus AI, Inc. | $12.3B | 22.79 | -49.9% | |
| BTSG | BrightSpring Health Services, Inc. Common Stock | $11.6B | |||
| HQY | HealthEquity, Inc. | $8.0B | 35.35 | 4.15 | |
| HNGE | Hinge Health, Inc. | $7.3B | |||
| WAY | Waystar Holding Corp. | $5.1B | 34.57 | 1.20 | 3.6% |
| DOCS | Doximity, Inc. | $4.9B | 30.07 | 5.33 | 17.0% |
| HTFL | Heartflow, Inc. Common Stock | $4.2B | 14.82 | -42.3% |
Price Performance
| 1 month | +1.17% |
| 3 months | -0.57% |
| Year-to-date | -27.62% |
| 1 year | -38.43% |
| 3 years | -83.43% |
| 5 years | -96.88% |
52-Week Range
| 52-week High | $3.62 |
| 52-week Low | $0.96 |
| Avg Volume (90d) | 1.3M |
Related companies: CRBU · ENTA · HSDT · NNOX · OBIO · OM · PRLD
Explore sector: Healthcare · Medical - Healthcare Information Services
More sections of HCAT: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks